These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25176981)

  • 1. Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.
    Merlini G; Palladini G
    Haematologica; 2014 Sep; 99(9):1407-9. PubMed ID: 25176981
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).
    Jaccard A; Comenzo RL; Hari P; Hawkins PN; Roussel M; Morel P; Macro M; Pellegrin JL; Lazaro E; Mohty D; Mercie P; Decaux O; Gillmore J; Lavergne D; Bridoux F; Wechalekar AD; Venner CP
    Haematologica; 2014 Sep; 99(9):1479-85. PubMed ID: 24859879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexamethasone and cyclophosphamide].
    Lu J; Wang H; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):345-8. PubMed ID: 23668210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
    Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
    Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse.
    Moscetti A; Saltarelli F; Bianchi MP; Monarca B; De Biase L; Porrini R; Antolino G; La Verde G
    Amyloid; 2011 Jun; 18 Suppl 1():152-4. PubMed ID: 21838469
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolated autonomic failure without evident somatic polyneuropathy in AL amyloidosis.
    Sugiyama A; Asahina M; Takeda Y; Shiojiri T; Sano K; Ikeda S; Kuwabara S
    Amyloid; 2014 Sep; 21(3):218-20. PubMed ID: 24970351
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
    Roussel M; Sachchithanantham S; Gibbs SD; Venner CP; Pinney JH; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2013 Sep; 162(6):856-8. PubMed ID: 23773011
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
    Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
    Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
    Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.
    Dispenzieri A
    Leukemia; 2014 Dec; 28(12):2273-5. PubMed ID: 25492370
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib in systemic AL amyloidosis: a single center experience.
    Coriu D; Badelita S; Talmaci R; Dobrea C; Dogaru M; Ostroveanu D; Crisan M
    Amyloid; 2011 Jun; 18 Suppl 1():148-50. PubMed ID: 21838467
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
    Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
    Kastritis E; Anagnostopoulos A; Roussou M; Toumanidis S; Pamboukas C; Migkou M; Tassidou A; Xilouri I; Delibasi S; Psimenou E; Mellou S; Terpos E; Nanas J; Dimopoulos MA
    Haematologica; 2007 Oct; 92(10):1351-8. PubMed ID: 18024372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effects and safety of bortezomib combined with dexamethasone in the treatment of primary systemic amyloidosis].
    Li J; Zhao Y; Zeng LJ; Su C; Wang HH
    Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):741-4. PubMed ID: 20079210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making light of an interstitial process.
    Thahseen A; Williams R; Gosney JR; Menzies D
    Am J Respir Crit Care Med; 2012 Nov; 186(9):926. PubMed ID: 23118084
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience.
    Abonour R; Kramer G; Suvannasankha A; Benson MD
    Amyloid; 2011 Jun; 18 Suppl 1():151. PubMed ID: 21838468
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.